CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination with Trastuzumab in Patients with Metastatic Breast Cancer
Journal of the National Comprehensive Cancer Network（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined